# reload+after+2024-01-21 03:38:13.916878
address1§60 Gracechurch Street
address2§6th Floor
city§London
zip§EC3V 0HR
country§United Kingdom
website§https://www.hemogenyx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.
fullTimeEmployees§14
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Vladislav  Sandler Ph.D.', 'age': 58, 'title': 'Co-Founder, CEO & Director', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 282000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Alexis M. Sandler J.D.', 'title': 'Independent Co-Founder & Non-Executive Director', 'fiscalYear': 2022, 'totalPay': 57000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Koen  Van Besien M.D., Ph.D.', 'title': 'Clinical Advisor & Medical Director', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§3.137
currency§GBp
exchange§LSE
quoteType§EQUITY
shortName§HEMOGENYX PHARMACEUTICALS PLC O
longName§Hemogenyx Pharmaceuticals Plc
firstTradeDateEpochUtc§1447056000
timeZoneFullName§Europe/London
timeZoneShortName§GMT
uuid§32fe4e24-6cc3-3b3e-9d4a-9e593f48249a
recommendationKey§none
quickRatio§4.074
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
